Expression of the oncogenic Epstein-Barr virus (EBV)-encoded Latent Membrane Protein 1 (LMP1) activates signalling on the NF-kB axis through two distinct domains in the cytoplasmic C-terminus of the protein, namely CTAR1 (aa 187 ± 231) and CTAR2 (aa 351 ± 386). Whilst this eect is responsible for some of the functional consequences of LMP1 expression, additional LMP1-mediated signalling pathways may exist which contribute to the pleiotropic activities of this protein. In this study we provide evidence of a kinase cascade being activated by LMP1. Thus, we demonstrate that stable or transient expression of the LMP1 prototype from B95.8 in cells of epithelial or B cell origin activates the c-Jun N-terminal kinase (JNK, also known as the stressactivated protein kinase, SAPK) pathway, an eect which was found to be mediated through CTAR2 but not CTAR1. LMP1 from the Cao viral strain or LMP1 homologues from the simian EBV naturally infecting baboons and rhesus monkeys were also able to activate JNK. This phenomenon translates to induction of AP-1, a transcription factor which is readily activated by growth factors and mitogens. Interestingly, an LMP1/ CD40 chimaera comprising of the N-terminus and transmembrane domain of LMP1 and the cytoplasmic tail of CD40 which shares a common TRAF binding motif with CTAR1, eectively induced JNK. As NF-kB and JNK are co-activated in LMP1-expressing cells, we investigated whether the two pathways are overlapping or independent. We have found that inhibition of NF-kB by metabolic inhibitors or a constitutively active mutated IkBa does not impair the ability of LMP1 to signal on the JNK axis. Conversely, whilst a dominant negative mutated SEK (JNKK) inhibited LMP1-induced JNK activation, it did not aect NF-kB suggesting that these two LMP1-mediated pathways are divergent.
Introduction
Among the nuclear and membrane proteins expressed as a consequence of Epstein-Barr virus (EBV) infection, the latent membrane protein 1 (LMP1) is of particular interest as it resembles a classical oncogene in its ability to induce growth transformation of certain rodent ®broblast cell lines (Wang et al., 1985; Baichwal and Sugden, 1988) . LMP1 expression is also essential for EBV-mediated primary B-cell transformation and is associated with a number of malignancies including Hodgkin's disease, undifferentiated nasopharyngeal carcinoma (NPC) and EBVrelated lymphoproliferative disease (Young and Rowe, 1992; Liebowitz and Kie, 1993) . In addition, expression of this viral oncogene in the absence of other EBV genes in B-cell lines can induce many of the phenotypic changes reminiscent of the activation process initiated by EBV infection, including upregulation of CD23, CD40 and CD54 (ICAM1) and the anti-apoptotic A20 protein (Wang et al., 1988 (Wang et al., , 1990 Laherty et al., 1992; Huen et al., 1995) . LMP1 expression in epithelial cells also results in upregulation of CD40, CD54 and A20 expression (Huen et al., 1995; Miller et al., 1997; Eliopoulos, Dawson and Young, unpublished observations) and blocks dierentiation, a property which may be important in the pathogenesis of NPC (Dawson et al., 1990; Fahraeus et al., 1990) .
LMP1 comprises a short 23 amino acid (aa) amino terminal cytoplasmic domain, 6 putative membranespanning domains of 162 aa which are important for conferring plasma membrane aggregation and a large 200 aa carboxyl terminal cytoplasmic domain. Mutational analysis has identi®ed two domains in the cytoplasmic C-terminus of LMP1 which are important for induction of phenotypic changes, the C-terminal activating region 1 (CTAR1, residues 194 ± 232) and CTAR2 (residues 351 ± 386) (Huen et al., 1995; Kaye et al., 1995) .
Whilst much is known about the functional consequences of LMP1 expression, the signalling events which mediate these eects are widely unknown. Recently, a family of related proteins which interact with the TNF receptor, so called TNF Receptor-associated factors (TRAFs), has been shown to associate with the carboxy terminus of LMP1 and appear to be important in mediating LMP1 signalling Devergne et al., 1996; . TRAF2 is of particular interest as it mediates activation of the transcription factor NF-kB upon LMP1 expression by an as yet unknown mechanism. TRAF1 and TRAF3 strongly associate with the proximal C-terminus of LMP1 (CTAR1) and may negatively in¯uence NF-kB, possibly by competing with TRAF2 for occupancy of the TRAF binding site (Eliopoulos et al., 1997) . The extreme C-terminus of LMP1 (CTAR2) appears to be the dominant NF-kB activating region of this protein in the majority of cell lines, an eect which may be indirectly in¯uenced by TRAF2 Eliopoulos et al., 1997) . Although NF-kB activation could explain some of the phenotypic changes induced by LMP1 expression (Rowe et al., 1994; Huen et al., 1995; Mitchell and Sudgen, 1995; Eliopoulos et al., 1997) , additional signalling pathways are likely to contribute to the pleiotropic eects of this protein.
The c-Jun N-terminal kinase (JNK, also known as the stress-activated protein kinase, SAPK) signalling cascade is initiated by a variety of stress factors including protein synthesis inhibitors, radiation, drugs and heat shock (Derijard et al., 1994; Zanke et al., 1996) . It is also readily activated upon stimulation of various members of the TNF receptor superfamily, including TNFRI, TNFRII, and CD40, an eect which is probably mediated through recruitment of TRAF2 to these receptors (Sakata et al., 1995; Berberich et al., 1996; Natoli et al., 1997; Reinhard et al., 1997) . Activation of JNK by stimulation of CD95 (Fas) has also been described (Lenczowski et al., 1997) . Signalling events leading to activation of the JNK pathway include the small GTPases Rac and Cdc42 which transmit the signal through the p21 activated protein kinase PAK and subsequently through the MEK kinases MEKK1, MEKK2 and MEKK3 to MKK4/SEK/JNKK. The latter may act as a direct activator of JNK and dominant negative SEK mutants can block signalling on the JNK axis (Sanchez et al., 1994; Yan et al., 1994) . The physiological consequenes of stimulation of this pathway are unclear. Recent reports suggest that activation of JNK/SAPK may mediate cell death in response to DNA damage and heat shock (Zanke et al., 1996) . The signi®cance of this pathway for TNFa or Fas-induced apoptosis is however controversial Natoli et al., 1997; Lenczowski et al, 1997) . A role for JNK in cell growth transformation has also been described (Dickens et al., 1997; Rodrigues et al., 1997) .
In this study we show that expression of the EBVencoded LMP1 signals for activation of the JNK pathway. Thus, stable or transient LMP1 expression in cells of epithelial or B-cell origin was found to induce JNK activation leading to the up-regulation of the transcription factor AP-1, a nuclear target for JNK. Interestingly, this eect is mediated by CTAR2 but not CTAR1. Activation of the NF-kB pathway also occurs in response to LMP1 expression but can be dissociated from that of JNK.
Results

Stable expression of LMP1 correlates with constitutive activation of JNK
To determine the eects of LMP1 on JNK pathway, HeLa cervical carcinoma, EJ bladder carcinoma and BL41 Burkitt lymphoma cell lines stably transfected with pSV2.gpt.MTLM plasmid, which directs expression of LMP1 from an inducible metallothionein promoter, were examined for JNK activity using immune complex kinase assays. As the metallothionein-inducible system is not tightly regulated, basal LMP1 expression was seen in all pSV2.gpt.MTLM clones tested in the absence of induction by heavy metals (Figure 1a) . Lysates from these cells were immunoprecipitated with a JNK-speci®c antibody and assayed for kinase activity with an NH 2 -terminal (residues 1 to 79) cJun-GST fusion protein as substrate. c-Jun has previously been shown to be an ecient substrate for JNK, being phosphorylated primarily on serine residues 63 and 73, both of which are critical for c-Jun function (Derijard et al., 1994) . In these in vitro kinase assays a correlation between LMP1 expression and JNK activity was observed. Thus, all stable LMP1 transfectants tested were found to possess elevated JNK activity (1.3-to 2.1-fold) compared to vector control-transfected cells, suggesting that stable LMP1 expression results in constitutive activation of JNK (Figure 1b) . In similar immune complex kinase assays, the anti-JNK-immunoprecipitate failed to phosphorylate GST control or GST-IkB fusion protein con®rming the speci®city of the eect (data not shown).
Transient expression of LMP1 mediates JNK activation
As stable LMP1 expression was found to mediate constitutive activation of JNK, the eects of transient expression of this viral protein on JNK activity were assessed. For this purpose, 293 cells which have high transfection eciency were transfected with increasing amounts (0, 0.2, 2 or 4 mg) of pSG5-LMP1, an SV40 early promoter-driven LMP1-expression vector, in the presence of 1 mg of HA-p46SAPKg-pcDNA3, a CMVdriven hemagglutinin (HA)-tagged JNK-expression vector. Epitope-tagged JNK expression vectors have been previously used to demonstrate activation of JNK by exogenous expression of TRAF2 (Natoli et al., 1997; Reinhard et al., 1997 Immune complex kinase assays showing elevated JNK activity in LMP1-transfected cells. For each cell line, JNK were immunoprecipitated from 250 mg of the same lysates used in (a) and tested for activity in an in vitro kinase assay using 2 mg GST-cJun as substrate. Lower panel; Relative levels of activation quantitated on a phosphorimager are shown with control samples given the arbitary value of one. Two independent experiments were performed and gave similar results precipitated with an HA-speci®c antibody and assayed for kinase activity in an immune-complex kinase assay using GST-cJun fusion protein as substrate. As shown in Figure 2a , increased levels of LMP1 expression as measured by Western blot analysis correlated with increased JNK activity. Immunoblot analysis of anti-HA immunoprecipitates using a JNK-speci®c antibody veri®ed that comparable amounts of HA-p46SAPKg-pcDNA3 were analysed (Figure 2a, lower panel) . The mean maximum increase in JNK activity as determined in a number of independent experiments was 5.7-fold above background and was observed using 4 mg of pSG5-LMP1 plasmid (Figure 2b) . Similar results were obtained with HeLa cervical carcinoma cells or SV40-transformed keratinocytes. Thus, transient transfection of these cell lines with 4 mg pSG5-LMP1 induced a 4.5-and 7.5-fold increase in JNK activity respectively.
In order to de®ne whether other naturally occurring LMP1 variants, in addition to the B95.8 strain used in these studies, could activate the JNK cascade, the Cao variant of LMP1 and the LMP1 homologues from the simian EBV naturally infecting baboons (Cercopithicine herpesvirus 12, Herpesvirus papio, HP10) and rhesus monkeys (Cercopithicine herpesvirus 15, RE1) (Franken et al., 1996) were expressed in 293 cells together with HA-p46SAPKg-pcDNA3 vector. Immune-complex kinase assays were performed using GST-cJun fusion protein as substrate and showed that all LMP1 variants tested could signi®cantly induce JNK activity (Figure 2c ).
Induction of LMP1 directly activates functional JNK
In order to demonstrate that LMP1 directly activates the JNK pathway, HeLa/LMP1 cl.2 cells were induced to express high levels of LMP1 by treatment with 6 mM cadmium chloride (CdCl 2 , Figure 3a ). This concentration of CdCl 2 was selected on the basis of optimal induction of LMP1 and lack of cellular toxicity over a 24 ± 72 h time-period. Induction of LMP1 following exposure of HeLa/LMP1 cl.2 cells to cadmium occurred within 3 h and was maximal at 12 ± 24 h of treatment ( Figure 3a and Eliopoulos et al., 1997) .
Lysates from cells treated with CdCl 2 were immunoprecipitated with a JNK-speci®c antibody and assayed for kinase activity. In these immune complex kinase assays, no increase in JNK activity was observed following a 2 hexposure, in agreement with the lack of induction of LMP1 expression at this time point. Rather, a consistent ®nding in these experiments was a slight reduction in JNK activity at 2 h of treatment compared to untreated HeLa/ LMP1 cl.2 cells. This eect was transient and was not observed at earlier time points (30 min to 1 h). Induction of LMP1 by CdCl 2 enhanced JNK activity, inducing a maximum of 1.8-fold increase after 3 h of treatment when compared to control HeLa/LMP1 cl.2 cells. A small decrease in the levels of JNK activation was then observed at 6 h of exposure and was followed by a further drop at 12 h of stimulation ( Figure 3a and b and data not shown). HA-JNK was immunoprecipitated from 250 mg of the same cell lysates as above using anti-HA antibody and kinase assays were performed as described in Materials and methods. JNK activity was assessed by the ability of the immunoprecipitate to phosphorylate GST-cJun substrate. Lower panel; Western blot analysis of anti-HA-immunoprecipitates using a JNK-speci®c antibody was also performed to demonstrate that comparable amounts of HA-p46SAPKg-pcDNA3 were analysed in cotransfection experiments. HeLa/gpt cl.1 HeLa/LMP1 cl.2
However, the levels of JNK activity at these two time points were still elevated compared to untreated LMP1-expressing HeLa cells. JNK levels in control cultures remained unaected. Results from ®ve independent experiments are summarised in the histogram of Figure  3b . Similar data were obtained with an additional HeLa/ LMP1 clone, demonstrating the generality of the observed phenomena. As LMP1 expression has been shown to activate the transcription factor NF-kB, experiments were carried out to determine whether JNK and NF-kB are coactivated in extracts from LMP1-expressing HeLa cells. Induction of NF-kB binding activity in CdCl 2 -treated HeLa/LMP1 cl.2 cells was determined by electrophoretic mobility shift assays (EMSAs) using a 32 P-labelled HIV-kB probe. Whilst the basal levels of NF-kB binding activity in nuclear extracts from LMP1 transfectants were higher than control vector-transfected cells consistent with the constitutive level of LMP1 expression, a further increase in NF-kB binding was observed after 3 h of treatment (Figure 3c ). However, no induction of NF-kB was observed at 2 h post-stimulation with CdCl 2 , in agreement with the lack of LMP1 induction and JNK activation at this time point. Using luciferase reporter assays we have veri®ed these results and found that basal LMP1 expression induces a constitutive ®vefold increase in NF-kB-dependent transactivation which can be further increased to 13-fold upon a 3 h-stimulation with cadmium. These experiments demonstrate that the kinetics of NF-kB and JNK activation following LMP1 induction are similar.
In order to demonstrate that the observed LMP1-mediated activation of JNK signalling is functional, the eects of LMP1 expression on the activity of the transcription factor AP-1, a nuclear target for the JNK cascade, were determined. For this purpose, EMSAs were performed with nuclear extracts from CdCl 2 -treated HeLa/gpt or HeLa/LMP1 cl.2 cells using a 32 Plabelled collagenase TRE oligo as probe. In these experiments, a signi®cantly higher basal AP-1 binding activity was observed in LMP1-expressing versus vector-transfected HeLa cells (Figure 3d ). Treatment with 6 mM CdCl 2 further increased AP-1 binding activity in HeLa/LMP1 cl.2 but not HeLa/gpt cl.1 cells with kinetics similar to those of JNK and NF-kB activation. Supershift experiments using antibodies speci®c for c-Jun, Fos, ATF2 or for an unrelated cRel protein showed that the activated AP-1 complex bound to collagenase promoter TRE contains Fos : Jun heterodimers (data not shown).
In order to determine whether increased AP-1 binding activity in HeLa/LMP1 cells translates to transcriptional activation of AP-1-responsive promoters, a set of reporter constructs consisting of two deletion mutants of the human collagenase promoter fused to the luciferase transcriptional unit was used. The 773 Col/ Luci construct contains the collagenase promoter TRE, whilst in the 763 Col/Luci derivative this site has been deleted (Angel et al., 1987; Antinore et al., 1996) . HeLa/ gpt or HeLa/LMP1 cells were transfected with these reporter constructs and 36 h later were treated with 6 mM CdCl 2 for 3 h to allow signi®cant activation of JNK before analysed for luciferase and b-gal activity. These experiments showed that 773 Col/Luci expression was signi®cantly induced by cadmium in HeLa/LMP1 but not HeLa control cells whilst the 763 Col/Luci construct that lacks functional AP-1 binding site failed to exhibit such a response in either of the two cell lines (Figure 3e ).
LMP1 induces JNK activation through its extreme C-terminus
Previous studies have implicated CTAR1 and CTAR2 in NF-kB activation and phenotypic changes induced by LMP1 (Huen et al., 1995; Eliopoulos et al., 1997) . The relative contribution of these domains to NF-kB activation is cell type-dependent with CTAR2 being the predominant eector domain in most cells. In order to identify whether these two domains are also important for JNK activation, LMP1 deletion mutants which remove the entire cytoplasmic tail (aa 194 ± 386), the CTAR1 domain (aa 187 ± 351) or CTAR2 (aa 332 ± 386) were used (Figure 4a ). Transient transfection of LMP1 deletion mutants in 293 cells and subsequent EMSAs demonstrated that CTAR2 rather than CTAR1 is the major contributor of NFkB in this cell line (Figure 4b ). These results were veri®ed by NF-kB-driven luciferase reporter assays (see Figure 4f) .
Lysates from 293 cells transfected with 4 mg of LMP1 constructs in the presence of 1 mg HAp46SAPKg-pcDNA3 and 100 ng b-galactosidase expression vector were prepared at 36 h post-transfection and analysed for LMP1 expression and JNK activity. Immunoblot analysis and b-galactosidase reporter assays veri®ed comparable levels of expression of LMP1 or LMP1 deletion mutants and similar transfection eciencies (data not shown). Immune complex kinase assays were performed and showed that removal of the entire cytoplasmic tail of LMP1 (construct D[194 ± 386] ) abrogated the ability of the protein to activate JNK, suggesting that the Cterminus of LMP1 is necessary for signalling on the JNK axis. Interestingly, whilst CTAR2 (construct D[187 ± 351]) eectively induced JNK activity to wild type levels, CTAR1 (construct D[332 ± 386]) failed to signal (Figure 4c, upper panel) . Immunoblot analysis of anti-HA-immunoprecipitates using a JNK-speci®c antibody was performed to verify that comparable amounts of HA-p46SAPKg-pcDNA3 were analysed (Figure 4c, lower panel) . Similar results were obtained in two additional experiments and are summarised in the histogram of Figure 4d .
The observed inability of CTAR1 to induce JNK was unexpected, as TRAF2 which binds and mediates JNK signalling from TNFRI, TNFRII and CD40 (Natoli et al., 1997; Reinhard et al., 1997; Eliopoulos and Young, unpublished data) also associates with the membrane proximal C-terminus of LMP1. A PxQxT motif in both the CTAR1 domain of LMP1 and CD40 cytoplasmic tail has been previously shown to be important for TRAF binding and induction of NF-kB Eliopoulos et al., 1997) . Thus, we determined whether an LMP1/CD40 chimaera (Figure 4a ) comprising of the LMP1 N-terminus/ transmembrane domain (aa 1 ± 192) and the CD40 cytoplasmic tail (aa 220 ± 278) would activate the JNK pathway. For this purpose, lysates from 293 cells transfected with 1 mg HA-p46SAPKg-pcDNA3 in the presence of 4 mg of pSG5-LMP1D[332 ± 386] or pSG5-LMP1/CD40 chimaera were subjected to immune complex kinase assays, using the same experimental approach described in the legend of Figure 4c . We have found that unlike CTAR1, the LMP1/CD40 chimaera eciently activated JNK, inducing a 3.5-fold increase in cJun-phosphorylation when compared to vector-transfected cells (Figure 4e, lanes 1 ± 3) . As positive control in these experiments, transfection of 293 cells with a CMV-driven CD40-expression vector and subsequent ligation with puri®ed CD40L was found to eciently activate JNK (Figure 4e, lane 4) . NF-kB-driven luciferase reporter assays were also performed to verify activation of NF-kB upon expression of the LMP1/CD40 chimaera (Figure 4f ).
JNK and NF-kB activation in response to LMP1 expression are distinct signalling pathways
As induction of LMP1 in HeLa cells co-activates JNK and NF-kB, we wished to establish whether the two pathways are overlapping or can be dissociated.
We ®rst examined whether inhibition of LMP1-mediated NF-kB by metabolic inhibitors could in¯uence the JNK cascade. For this purpose, HeLa/ LMP1 cl.2 cells were treated with 6 mM CdCl 2 for 3 h to allow signi®cant activation of NF-kB and JNK, in the presence or absence of the metabolic inhibitor D609. This compound has been previously shown to prevent nuclear translocation of NF-kB and subsequent NF-kB transactivation in response to a variety of stimuli, including LMP1 expression (Schutze et al., 1992; Eliopoulos et al., 1997) . In agreement with these reports, exposure of cadmium-treated HeLa/LMP1 cells to 25 mg ml 71 D609 signi®cantly inhibited NFkB binding (Figure 5a, upper panel) . Lysates from identical cultures were analysed for JNK activity. It was found that far from reducing kinase activity, D609 dramatically increased JNK activation in response to LMP1 expression (Figure 5a , middle and lower panels). EMSAs were also performed with the same nuclear extracts used for the NF-kB determination and veri®ed that the observed increase in JNK activity translates to AP-1 activation. This is in agreement with previous reports suggesting that antioxidants can potently increase AP-1 levels in response to treatment with inducers of NF-kB such as U.V. radiation, drugs or anti-CD40 antibodies (Berberich et al., 1996; Wesselborg et al., 1997) . Our data demonstrate that compounds which eciently block the LMP1-mediated NF-kB activation in HeLa cells do not impair its ability to induce the JNK pathway.
As however, these inhibitors may also impinge on pathways other than NF-kB, we used a constitutively active IkBa mutant to target more speci®cally LMP1-mediated NF-kB. IkB sequesters latent NF-kB in an inactive form in the cytoplasm. Following stimulation, IkBa is phosphorylated at Serine residues 32 and 36 and degraded which leads to NF-kB translocation to the nucleus and activation of target genes. The IkBa construct used in our studies contains a double Serine to Alanine (S32A/S36A) mutation, which inhibits degradation of this protein rendering it a constitutively active molecule (Lee et al., 1997) . Thus, transient transfection of pc-IkBa(S32A/S36A) into HeLa/LMP1 cells signi®cantly inhibited NF-kB-dependent luciferase activity upon treatment with CdCl 2 , inducing a 60 ± 70% reduction in RLV (Figure 5b ). We subsequently determined the eects of a dominant negative SEK1 (JNKK) mutant (SEK1(K129R)) on LMP1-mediated NF-kB. SEK1 is the upstream kinase of JNK and dominant negative SEK1 mutants have been shown to block JNK activity in response to a variety of stimuli (Sanchez et al., 1994; Yan et al., 1994) . We found that unlike IkBa(S32A/S36A), over-expression of The metabolic inhibitor D609 blocks LMP1-mediated NFkB but not JNK activity. HeLa/LMP1 cl.2 cells were exposed for 3 h to 6 mM CdCl 2 in the presence or absence of 25 mg ml 71 D609. Nuclear extracts were isolated and analysed for NF-kB binding activity using EMSAs (upper panel). Lysates from the same cultures were analysed for JNK activation (middle panel). Lower panel; Relative levels of JNK activation quantitated on a phosphorimager are shown. Two independent experiments were performed and gave similar results. (b) A constitutively active mutated IkBa (IkBa(S32A/ S36A)) but not a dominant negative SEK1 (SEK1(K129R), blocks LMP1-induced NF-kB. HeLa/gpt (CON, lanes 1, 3 and 5) or HeLa/ LMP1 cl.2 cells (LMP1, lanes 2, 4 and 6) were transfected with 2.5 mg IkBa(S32A/S36A) or SEK1(K129R) expression vector or 2.5 mg control plasmid in the presence of 1 mg of the NF-kB luciferase reporter plasmid kBconA-Luc and 1 mg of b-galactosidase expression vector. Twenty-four hours later, cells were treated for 3 h with 6 mM CdCl 2 to eectively activate LMP1 signalling. Luciferase and b-gal activities were assessed; relative luciferase values (RLV) represent the luciferase values normalized on the basis of b-galactosidase expression. The mean (+s.d.) of duplicate determinations of three independent experiments is shown. (c) SEK1(K129R) but not IkBa(S32A/S36A) inhibits LMP1-mediated JNK. The eect of these mutated molecules on LMP1-mediated JNK activation was assessed by immune complex kinase using lysates from HeLa/gpt (CON, lanes 1, 3 and 5) or HeLa/LMP1 cells (LMP1, lanes 2, 4 and 6) transiently transfected with 2.5 mg IkBa(S32A/S36A) (lanes 3 and 4) or SEK1(K129R) (lanes 5 and 6) or control vector (lanes 1 and 2) in the presence of 1 mg of HA-p46SAPKg-pCDNA3. Twenty-four hours later, cells were treated for 3 h with 6 mM CdCl 2 , HA-JNK were immunoprecipitated from 350 mg of cell lysates using 2 mg of anti-HA antibody and kinase assays were performed as described in Materials and methods. A representative autoradiograph is shown (upper panel). Relative activities from three independent experiments were determined and depicted in histogram form (lower panel) SEK1(K129R) in HeLa/LMP1 cl.2 cells failed to inhibit LMP1-mediated NF-kB (Figure 5b) .
In order to determine the eects of constitutive active IkBa on JNK activity, HeLa/gpt or HeLa/ LMP1 cells were transfected with 1 mg HAp46SAPKg-pcDNA3 in the presence or absence of 2.5 mg pc-IkBa(S32A/S36A) expression vector. Twenty-four hours later, cells were treated for 3 h with 6 mM CdCl 2 to allow sucient activation of LMP1 signalling and lysates were subjected to immune complex kinase assay using GST-cJun as substrate. These experiments demonstrated that inhibition of NF-kB by IkBa(S32A/S36A) did not impair the ability of LMP1 to activate JNK ( Figure  5c , upper and middle panels). A small decrease in JNK activity observed in these experiments could be attributed to a decrease in viability and LMP1 expression conferred by IkBa in HeLa/LMP1 cells (data not shown; Eliopoulos et al., in preparation) . In this context, a consistent decrease in JNK protein levels immunoprecipitated from IkBa-expressing cells was observed (Figure 5c , lower panel). Unlike mutated IkBa however, over-expression of dominant negative SEK dramatically inhibited LMP1-mediated JNK activity, including an approximately 90% decrease in cJun substrate phosphorylation levels (Figure 5c ).
Discussion
The EBV-encoded LMP1 is a protein with pleiotropic activities. LMP1 expression induces growth transformation in rodent ®broblast cell lines (Wang et al., 1985; Baichwal and Sugden, 1988) , immortalization in normal B cells (Liebowitz and Kie, 1993) , upregulation of various phenotypic markers in cell lines of epithelial or B cell origin (Rowe et al., 1994; Huen et al., 1995; Miller et al., 1997) , cytokine production (Nakagomi et al., 1994; Eliopoulos et al., 1997) and dierentiation blockade in epithelial cells (Dawson et al., 1990; Fahraeus et al., 1990) . Cytostatic/cytopathic eects on certain cell types have also been described (Hammerschmidt et al., 1989; Eliopoulos et al., 1996; Floettmann et al., 1996; Lu et al., 1996) . The signalling events which mediate these activities are widely unknown. Although LMP1 readily activates NF-kB, this pathway could explain only some of the functional properties of LMP1 expression.
In this study we provide evidence of a second signalling pathway being activated by LMP1. Thus, we have shown that stable or transient LMP1 expression in cell lines of epithelial or B cell origin can activate the cJun N-terminal kinase (JNK) cascade. The levels of JNK activity in stable LMP1 clones were relatively low (1.3-to 2.1-fold). Constitutive low JNK activity could however be biologically signi®cant as it translates to constitutive activation of the transcription factor AP-1, a downstream eector molecule of the JNK cascade. Transient transfection of a number of naturally occurring LMP1 variants into 293 cells dramatically activated JNK in a dose-dependent manner. To exclude the possibility that induction of an autocrine loop through the secretion of NF-kB-induced factors is responsible for JNK activation, HeLa cells stably transfected with a metallothionein-regulated LMP1-expression vector were induced to express high levels of LMP1 by treatment with CdCl 2 . In these experiments, induction of LMP1 above basal levels was observed as early as 3 h post-stimulation. JNK and NF-kB activity paralleled induction of LMP1 in HeLa cells, suggesting that this viral protein can directly activate the JNK pathway. In addition, conditioned medium from vector or LMP1-expressing 293 cells were used to treat untransfected 293 cultures. These experiments showed that none of the conditioned media was able to induce JNK activation above background (data not shown), further supporting that the observed LMP1-mediated eect is direct.
LMP1 activates signalling on the NF-kB axis through two distinct domains in the cytoplasmic Cterminus of the protein, namely CTAR1 (aa 187 ± 231) and CTAR2 (aa 351 ± 386). The relative contribution of these two regions to NF-kB levels is cell contextdependent (Huen et al., 1995; Eliopoulos et al., 1997) , with CTAR2 being the most prominent contributor in the majority of cell lines, including 293 cells. In order to determine whether the same domains are important for JNK activation, we have used LMP1 deletion mutants which remove the entire cytoplasmic Cterminus, the CTAR1 region or CTAR2. We have found that deletion of the cytoplasmic tail impaired the ability of LMP1 to activate JNK, suggesting that this eect depends on intact C-terminal sequences. Interestingly, deletion of CTAR1 had no eect on the ability of LMP1 to activate JNK, whilst deletion of CTAR2 decreased it to background levels. Thus, although CTAR1 has been shown to be critical for LMP1-mediated transformation (Kaye et al., 1995) , the CTAR2 domain appears to be the primary regulator of LMP1 signalling.
As ectopic expression of LMP1 results to cytotoxicity in certain cell systems, it could be argued that activation of the JNK pathway is a non-speci®c cellular stress response induced by LMP1 overexpression. However, two lines of evidence argue against this possibility. First, cell lines stably transfected with LMP1 demonstrate constitutively activated JNK and second, LMP1-mediated cytotoxicity has been mapped to the proximal C-terminal sequences of the protein (Hammerschmidt et al., 1989; Eliopoulos et al., 1996) , which are impaired in JNK signalling.
As JNK and NF-kB are co-activated in HeLa cells we wished to establish whether these pathways run on the same axis or in parallel. We have found that inhibition of NF-kB by treatment with the metabolic inhibitor D609 or by expression of constitutive active IkBa mutant did not impair the ability of LMP1 to activate JNK. Conversely, whilst a domaint negative SEK mutant (SEK1(K129R)) inhibited JNK activation, it had no eect on LMP1-induced NF-kB. Thus, our data at this juncture favor a model in which JNK and NF-kB are located on parallel pathways. This conclusion is endorsed by the observation that JNK immunoprecipitated from LMP1-transfected cells failed to phosphorylate GST-IkBa fusion protein. However, we cannot rule out the possibility that a common component of both JNK and NF-kB pathways lies upstream of SEK and IkBa in LMP1-expressing cells. This also raises the question of a possible role for TRAF2. This molecule strongly binds TNFRII and CD40 and mediates NF-kB and JNK activation upon engagement of these receptors. Interestingly, TRAF2 weakly associates with the CTAR1 domain of LMP1, through a PxQxT motif necessary for interaction. However, our data argue against a role for TRAF2 in LMP1-mediated JNK activation. Thus, whilst CTAR1 activates NF-kB in 293 cells, it does not induce JNK. In addition, expression of SEK1(K129R) mutant signi®cantly inhibits LMP1-mediated JNK activation but the eect on TRAF2-induced JNK activity is controversial (Natoli et al., 1997; Reinhard et al., 1997) . Finally, no direct association of TRAF2 and CTAR2 has been so far identi®ed. These lines of evidence suggest that a protein other than TRAF2 is possibly required for LMP1-mediated JNK activation. We are currently using a yeast-two-hybrid approach to identify the adaptor protein(s) responsible for the observed eect.
As with the CTAR1 domain of LMP1, the CD40 cytoplasmic tail contains a PxQxT motif important for interaction with TRAFs and NF-kB activation. Unlike CTAR1 however, CD40 ligation and interestingly, expression of an LMP1/CD40 chimaera can activate the JNK pathway. Thus, the presence of a PxQxT motif is not the sole determinant of JNK activation and adjacent sequences may in¯uence TRAF binding and signalling (Franken et al., 1996; Eliopoulos et al., 1997) . This could possibly explain the observation that the CD40 C-terminus binds TRAF2 strongly but LMP1 only weakly (Rothe et al., 1995; and that CTAR1 is defective in activating JNK. The ability of the LMP1/CD40 chimaera to activate both JNK and NF-kB further supports the role of the LMP1 membrane spanning domain in the self-aggregation responsible for constitutive LMP1 function.
Among the substrates of JNK are cJun/AP-1 (Derijard et al., 1994) , ATF2 (Gupta et al., 1995) and Elk-1 (Whitmarsh et al., 1995) . Induction of these transcription factors could in turn activate target genes important for proliferation, dierentiation and transformation. The functional implications of activating the JNK cascade in LMP1-expressing cells will be an interesting subject for future studies.
Materials and methods
Cell lines and reagents
The human bladder carcinoma cell line EJ, the cervical HeLa and the Burkitt lymphoma cell line BL41 were continuously maintained in RPMI 1640 medium (Gibco, UK) supplemented with 10% fetal calf serum (FCS) and 2 mM glutamine. 293 human kidney embryonic cells were cultured in Dulbecco's Modi®ed Eagle's (DME) medium supplemented with 10% fetal calf serum (FCS) and 2 mM glutamine. SV40-transformed human keratinocytes (SV-AR-K) were grown in Joklics/8% FCS in the presence of 2 mM glutamine, 0.4 mg/ml hydrocortisone (Gibco) and 10 ng ml 71 cholera toxin. The xanothogenate compound D609 (tricyclodecan-9-ylxanthogenate potassium) was purchased from Calbiochem (LaJolla, California, USA) and dissolved in growth medium immediately before use. Puri®ed CD40L was kindly provided by Dr Richard Armitage (Immunex Corporation, Seattle, USA). TNFa was purchased from R&D Systems.
DNA constructs, transfection and reporter assays pSG5-based LMP1 and LMP1 deletion mutants have been previously described (Huen et al., 1995) . The pSG5-based expression vectors for the Cao variant of LMP1 and for the LMP1 homologs from baboon and rhesus EBV were kindly provided by Prof M Rowe (University of Wales Medical School, Cardi, UK) and Dr F Wang (Harvard Medical School, Boston, USA) respectively.
The HA-p46SAPKg-pcDNA3 vector was a gift from Dr J Woodgett (The Ontario Cancer Institute, Ontario, Canada) and the IkBa (S32A/S36A) cDNA was kindly provided by Dr J Girdlestone (University of Birmingham Medical School, Birmingham, UK) in a Bluescript vector. To generate a CMV-driven IkBa (S32A/S36A)-expression vector, the cDNA was excised from pBluescript-SK + as EcoRI/EcoRI fragment and inserted into pcDNA3 (Invitrogen) to give pc-IkBa(S32A/S36A). The 773 Col/Luci and 763 Col/Luci reporter constructs (Angel et al., 1987) were kindly provided by Dr D McCance, Rochester University, NY, USA. A CD40-expression vector was generated by ampli®cation of cDNA prepared from EJ cells using CD40-speci®c primers with arti®cial HindIII (5'-CTGGTCTAAGCTTGCCATGGTTC-3', forward primer) or NotI sites (5'-TGGGTGGCGGCCGCCTCACT-3', reverse primer). The PCR product was digested with HindIII and NotI, inserted into the HindIII/NotI sites of pcDNA3 and sequenced.
For the generation of the LMP1/CD40 chimaera, an arti®cial KpnI site was ®rst created at the LMP1 codon which corresponds to amino acid 192, using the QuickChange TM site-directed mutagenesis kit of Stratagene and pSG5-LMP1 as substrate. The cytoplasmic C-terminus of LMP1 was then removed by digestion with KpnI and BamHI. CD40 sequences which correspond to amino-acids 220 ± 278 were PCR-ampli®ed from pcDNA3-CD40 using a 5'-primer with an arti®cial KpnI site (5'-CAAAAAGGGTACCAA-GAAGCC-3') and a 3'-primer with an arti®cial BamHI site (5'-GTGGGTGGATCCTCACTGTCTCT-3'). The PCR product was digested with KpnI and BamHI and inserted in frame into the N-terminal/transmembrane sequences of LMP1. Sequencing was performed to verify the above changes.
Stable LMP1-expressing HeLa, EJ and BL41 cells have been previously described (Rowe et al., 1994; Eliopoulos et al., 1996 Eliopoulos et al., , 1997 . For transient transfections in 293 cells a standard calcium phosphate technique was used. Transient transfections in SV-AR-K and HeLa cells were performed using a modi®cation of DEAE-dextran method which gives high transfection eciency (Gonzalez and Joly, 1995; Eliopoulos et al., 1996) .
Luciferase reporter and b-galactosidase assays were performed as previously described (Eliopoulos et al., 1997) .
Immunoprecipitations, kinase assays and immunoblotting
Following stimulation or transfection, cells were lysed in 300 ± 500 ml of kinase lysis buer (20 mM Tris pH 7.6, 0.5% Triton X-100, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 2 mM sodium vanadate, 10 mg/ml aprotinin, 10 mg/ ml leupeptin and 1 mM DTT) for 15 min on ice. Cell debris were removed by centrifugation and protein concentration was determined using a commercially available Biorad protein assay. c-Jun N-terminal kinases were immunoprecipitated from 250 mg total protein extracts (unless otherwise stated) using 1 mg JNK1 (C-17; Santa Cruz) antibody or 2 mg anti-HA (Boehringer) for the experiments involving HA-tagged JNK-expression vector and 25 ml of protein G-sepharose (Pharmacia) for 2 ± 3 h. Following immunoprecipitation, beads were washed once with kinase lysis buer and twice with assay buer (20 mM HEPES pH 7.5, 20 mM b-glycerophosphate, 10 mM MgCl 2 , 1 mM DTT, 50 mM sodium vanadate and 1 mg/ml leupeptin).
After the last wash, the beads were drained using a ®ne gauge Hamilton syringe and resuspended in 40 ml assay buer containing 2 mg GST-Jun substrate (Stratagene), 20 mM cold ATP and 3 mCi [g-32 P]ATP. Kinase reactions were carried out at 308C for 30 min and stopped by addition of 40 ml of 66Laemmli buer and boiling for 5 min. Samples were then analysed on a 10% SDSpolyacrylamide gel. The gel was then stained with coomassie blue to verify that equal amounts of substrate were used and autoradiography and phosphorimaging were performed after the gels were dried. Western blot analysis of anti-HA-immunoprecipitates using a JNK-speci®c antibody was also performed to demonstrate that comparable amounts of HA-p46SAPKg-pCDNA3 were analysed in cotransfection experiments.
For LMP1 immunoblotting, 50 mg of total cell lysates isolated as described above were analysed on a 10% gel and LMP1 expression was detected with the anti-LMP1 mAbs CS.1-4. Immune complexes were detected with [ 
Electrophoretic mobility shift assays
Cell nuclei isolated by resuspending cells in a solution containing 10 mM HEPES (pH 7.9), 1.5 mM magnesium chloride, 10 mM potassium chloride, 0.5 mM (DTT) and protease inhibitors were subjected to lysis in a buer constituting 20 mM HEPES (pH 7.9), 25% glycerol, 1.5 mM magnesium chloride, 0.42 M sodium chloride, 0.2 mM EDTA, 0.5 mM (DTT) and protease inhibitors. Protein concentration of isolated nuclear extracts was determined by the Biorad protein assay, according to
